India Pharma Outlook Team | Thursday, 14 May 2026
Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences, has signed a deal with Assertio Holdings, Inc., through its wholly-owned subsidiary, Zara Merger Sub Inc., marking its entry into the US Oncology market.
As per the deal, Zydus will make its move into the US oncology market by acquiring the outstanding shares of Assertio for USD 23.50 per share in cash. This makes the whole deal worth approximately USD 166.4 M on a fully diluted basis.
Sharvil P. Patel, Managing Director, Zydus Lifesciences Ltd, said, “This transaction represents a strategic step in strengthening our specialty and oncology footprint in the U.S. Assertio brings a focused commercial platform and an approved oncology asset that aligns well with our long-term strategy of building differentiated, durable specialty businesses globally.”
The tender is expected to launch within five business days post the agreement being signed. The deal is expected to close in the financial year 2026-27. The entire transaction is structured as a tender followed by a merger. Tender closing will be subject to customary closing conditions, including the tender of shares representing at least a majority of the total number of outstanding shares of Assertio common stock. Any shares not tendered in the offer will be acquired at the same price through the subsequent merger at the same price as per the tender offer.
Also Read: Role of Optical Imaging in Early Cancer Detection and Treatment
At the heart of this acquisition is a significant asset – ROLVEDON (eflapegrastim?xnst), a long-acting G-CSF biologic approved by the USFDA via a Biologics License Application (BLA). It focuses on preventing febrile neutropenia in adult cancer patients undergoing myelosuppressive chemotherapy.
Febrile neutropenia refers to a dangerous drop in neutrophils, a type of white blood cell, triggered by chemotherapy. It is one of the most common and dangerous complications in cancer treatment. Unlike daily injections, ROLVEDON is administered just once per chemotherapy cycle.
By acquiring an already approved and marketed product, Zydus intends to leverage Assertio’s focused commercial infrastructure and oncology relationships to expand its foothold in the US oncology market. This move will provide a faster and lower-risk path for Zydus to the oncology market rather than starting from scratch.
Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) is a leading multinational pharmaceutical organization headquartered in Ahmedabad. The company focuses on manufacturing generic drugs, biologics, vaccines, and active pharmaceutical ingredients (APIs). Zydus Lifesciences has also made its move into the French market with a EUR 70,000 deal with FBC Medicals finalized on April 30, 2026.
Pankaj Ramanbhai Patel, chairman of Zydus Lifesciences, on May 11, announced a donation of Rs 500 Cr for setting up Zydus Sardardham University in Ahmedabad. He made this announcement in the inauguration function of Sardardham-3 in Vadodara in the presence of Prime Minister Narendra Modi.
.jpg)
.jpg)
